Navigating ANCA-Associated Vasculitis Management

This chapter explores the complexities of diagnosing and managing ANCA-associated vasculitis, particularly in critically ill patients. It discusses treatment options, including the roles of rituximab, cyclophosphamide, and the newer C5A inhibitor Avacopan, while emphasizing careful patient selection and the importance of collaborative decision-making among specialists. The chapter also highlights evolving guidelines, monitoring strategies, and the impact of COVID-19 on treatment considerations.